目次

1. US Bispecific Antibodies Market Outlook
1.1 US Commercially Approved Bispecific Antibodies
1.2 US Bispecific Antibodies Market Current Scenario
1.3 US Bispecific Antibodies Clinical Development & Commercial Collaborative
Perspective
1.4 US Bispecific Antibodies Market Future Outlook

2. US Bispecific Antibodies Market Trends by Indication
2.1 Cancer
2.2 Ophthalmology
2.3 Autoimmune & Inflammatory Diseases
2.4 Blood Disorders

3. US Bispecific Antibodies Reimbursement Scenario
3.1 Medicare
3.2 Medicaid
3.3 Private Insurers
3.4 Pharmaceutical Companies
3.5 Approved Bispecific Antibodies Reimbursement Policies

4. Blincyto: 1st Approved Bispecific Antibody
4.1 Overview & Patent Insight
4.2 Pricing & Dosage Analysis
4.3 Sales Analysis

5. Hemlibra: 2nd Approved Bispecific Antibody
5.1 Overview
5.2 Dosage & Price Analysis
5.3 Sales Analysis

6. Rybrevant: 3rd Approved Bispecific Antibody
6.1 Overview
6.2 Dosage & Price Analysis
6.3 Sales Analysis

7. Kimmtrak: 4th Approved Bispecific Antibody
7.1 Overview
7.2 Pricing & Dosage Insight
7.3 Sales Analysis

8. Vabysmo: 5th Approved Bispecific Antibody
8.1 Overview
8.2 Dosage & Price Analysis
8.3 Sales Analysis

9. Lunsumio: 6th Approved Bispecific Antibody
9.1 Overview & Patent Insight
9.2 Dosage & Price Analysis
9.3 Sales Analysis

10. Tecvayli: 7th Approved Bispecific Antibody
10.1 Overview & Patent Insight
10.2 Pricing & Dosage Insight

11. Columvi: 8th Approved Bispecific Antibody
11.1 Overview & Patent Insight
11.2 Pricing & Dosage Insight

12. Epkinly: 9th Approved Bispecific Antibody
12.1 Overview & Patent Insight
12.2 Pricing & Dosage Insight

13. Talvey: 10th Approved Bispecific Antibody
13.1 Overview
13.2 Pricing & Dosage Insight

14. Elrexfio: 11th Approved Bispecific Antibody
14.1 Overview
14.2 Pricing & Dosage Insight

15. US Bispecific Antibodies Clinical Pipeline Overview
15.1 By Phase
15.2 By Biomarker
15.3 By Company
15.4 By Indication
15.5 Patient Segment

16. US Bispecific Antibodies Clinical Pipeline By Company, Indication & Phase
16.1 Research
16.2 Preclinical
16.3 Phase-I
16.4 Phase-I/II
16.5 Phase-II
16.6 Phase-II/III
16.7 Phase-III

17. US Marketed Bispecific Antibodies Clinical Insight By Company & Indication

18. Competitive Landscape
18.1 AbbVie
18.2 ABL Bio
18.3 Abpro Therapeutics
18.4 Abzyme Therapeutics
18.5 Affimed Therapeutics
18.6 Agenus
18.7 Amberstone Biosciences
18.8 Amgen
18.9 Antibody Therapeutics
18.10 Aptevo Therapeutics
18.11 Astellas Pharma
18.12 AstraZeneca
18.13 BioAtla
18.14 Boehringer Ingelheim
18.15 Bristol-Myers Squibb
18.16 Chugai Pharmaceutical
18.17 CytomX Therapeutics
18.18 Cytovia Therapeutics
18.19 Dren Bio
18.20 Elpis Biopharmaceuticals
18.21 EpimAb Biotherapeutics
18.22 Genentech
18.23 Genmab
18.24 GO Therapeutics
18.25 Harbour BioMed
18.26 IGM Biosciences
18.27 ImmunoPrecise Antibodies
18.28 Innovent Biologics
18.29 Integral Molecular
18.30 Invenra
18.31 Janssen Biotech
18.32 Kenjockety Biotechnology
18.33 L and L Biopharma
18.34 MacroGenics
18.35 Marengo Therapeutics
18.36 Memorial Sloan-Kettering Cancer Center
18.37 Merus
18.38 NovaRock Biotherapeutics
18.39 Pfizer
18.40 Phanes Therapeutics
18.41 QLSF Biotherapeutics
18.42 Regeneron Pharmaceuticals
18.43 Revitope
18.44 Roche
18.45 Surrozen
18.46 Talem Therapeutics
18.47 Virtuoso Therapeutics
18.48 Xencor
18.49 Zhejiang Shimai Pharmaceutical
18.50 Zymeworks